Clearside Biomedical (CLSD) said Wednesday its China-based partner, Arctic Vision, has received regulatory approvals in Australia and Singapore for Arcatus, an injection therapy for the treatment of uveitic macular edema.
Arcatus is the brand name used for Clearside's Xipere medication outside the US.
Arctic Vision, which has the exclusive license for the commercialization and development Xipere in the Asia-Pacific region, has received approvals for its new drug applications for Arcatus from the Therapeutic Goods Administration of Australia and the Health Sciences Authority in Singapore, Clearside said.
Shares of Clearside were up about 2% in recent trading.
Price: 0.94, Change: +0.02, Percent Change: +1.92
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.